Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Masao Tsukazaki is active.

Publication


Featured researches published by Masao Tsukazaki.


Bioorganic & Medicinal Chemistry Letters | 2003

Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole

Jun Ohwada; Masao Tsukazaki; Tadakatsu Hayase; Nobuhiro Oikawa; Yoshiaki Isshiki; Hiroshi Fukuda; Eisaku Chugai Seiyaku Kabushiki Kaiha Mizuguchi; Masahiro Sakaitani; Yasuhiko Shiratori; Toshikazu Yamazaki; Shigeyasu Ichihara; Isao Umeda; Nobuo Shimma

A highly potent water soluble triazole antifungal prodrug, RO0098557 (1), has been identified from its parent, the novel antifungal agent RO0094815 (2). The prodrug includes a triazolium salt linked to an aminocarboxyl moiety, which undergoes enzymatic activation followed by spontaneous chemical degradation to release 2. Prodrug 1 showed high chemical stability and water solubility and exhibited strong antifungal activity against systemic candidiasis and aspergillosis as well as pulmonary aspergillosis in rats.


Bioorganic & Medicinal Chemistry Letters | 2001

Synthesis and antifungal activities of novel 1,3-β-D-glucan synthase inhibitors. Part 1

Kazunao Masubuchi; Takehiro Okada; Masami Kohchi; Takeshi Murata; Masao Tsukazaki; Osamu Kondoh; Toshikazu Yamazaki; Yasuko Satoh; Yoshinori Ono; Toshiyuki Tsukaguchi; Kazuko Kobayashi; Naomi Ono; Tomoaki Inoue; Ikuo Horii; Nobuo Shimma

Highly potent 1,3-beta-D-glucan synthase inhibitors 10, 11 and 13 have been identified by the chemical modification of the fungicidal macrocyclic lipopeptidolactone, RO-09-3655 (1), isolated from the cultured broth of Deuteromycotinia spp. D-Ornithine derivative (10) showed improved antifungal activity in the systemic candidiasis model in mice and reduced hepatotoxicity in vitro, as compared with 1.


Archive | 1999

Azoles for treatment of fungal infections

Tadakatsu Hayase; Shigeyasu Ichihara; Yoshiaki Isshiki; Pingli Liu; Jun Ohwada; Toshiya Sakai; Nobuo Shimma; Masao Tsukazaki; Isao Umeda; Toshikazu Yamazaki


Archive | 1999

3-[4-(4-cyanophenyl)thiazol-2-y)]-1-(1h-1,2,4-triazol-1-yl)-butan-2-ol derivatives having antifungal activity

Tadakatsu Hayase; Shigeyasu Ichihara; Yoshiaki Isshiki; Pingli Liu; Jun Ohwada; Toshiya Sakai; Nobuo Shimma; Masao Tsukazaki; Isao Umeda; Toshikazu Yamazaki


Archive | 2000

N-substituted carbamoyloxyalkyl-azolium derivatives

Hiroshi Fukuda; Tadakatsu Hayase; Eisaku Mizuguchi; Nobuo Shimma; Jun Ohwada; Nobuhiro Carlton Pla Ka Oikawa; Masahiro Sakaitani; Masao Tsukazaki; Isao Imp Higashi Hakurak Umeda


Archive | 2002

CONDENSED CAMPTOTHECINS AS ANTITUMOR AGENTS

Takeshi Murata; Satoshi Niizuma; Nobuo Shimma; Hitomi Suda; Masao Tsukazaki


Archive | 2009

Novel process for the preparation of hexacyclic compounds

Hiroshi Fukuda; Takeshi Murata; Satoshi Niizuma; Hitomi Suda; Masao Tsukazaki


Archive | 2004

Hexacyclic compounds and their therapeutic use

Takeshi Murata; Satoshi Niizuma; Nobuo Shimma; Hitomi Suda; Masao Tsukazaki


Archive | 2004

Process for the preparation of hexacyclic compounds

Hiroshi Fukuda; Takeshi Murata; Satoshi Niizuma; Hitomi Suda; Masao Tsukazaki


Archive | 2004

Intermediates for N-substituted carbamoyloxyalkyl-azolium derivatives

Hiroshi Fukuda; Tadakatsu Hayase; Eisaku Mizuguchi; Nobuo Shimma; Jun Ohwada; Nobuhiro Oikawa; Masahiro Sakaitani; Masao Tsukazaki; Isao Umeda

Collaboration


Dive into the Masao Tsukazaki's collaboration.

Top Co-Authors

Avatar

Nobuo Shimma

Chugai Pharmaceutical Co.

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge